|
1
|
Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates.
|
Hum Gene Ther
|
2012
|
2.42
|
|
2
|
Image-guided convection-enhanced delivery platform in the treatment of neurological diseases.
|
Neurotherapeutics
|
2008
|
1.79
|
|
3
|
Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain.
|
Exp Neurol
|
2005
|
1.78
|
|
4
|
A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.
|
Mol Ther
|
2006
|
1.77
|
|
5
|
Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging.
|
Brain Res Brain Res Protoc
|
2005
|
1.74
|
|
6
|
Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.
|
Hum Gene Ther
|
2012
|
1.70
|
|
7
|
Efficient gene therapy-based method for the delivery of therapeutics to primate cortex.
|
Proc Natl Acad Sci U S A
|
2009
|
1.70
|
|
8
|
An engineered zinc finger protein activator of the endogenous glial cell line-derived neurotrophic factor gene provides functional neuroprotection in a rat model of Parkinson's disease.
|
J Neurosci
|
2010
|
1.59
|
|
9
|
Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response.
|
Hum Gene Ther
|
2009
|
1.55
|
|
10
|
Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.
|
Mol Ther
|
2012
|
1.55
|
|
11
|
Real-time MR imaging of adeno-associated viral vector delivery to the primate brain.
|
Neuroimage
|
2008
|
1.53
|
|
12
|
Strong cortical and spinal cord transduction after AAV7 and AAV9 delivery into the cerebrospinal fluid of nonhuman primates.
|
Hum Gene Ther
|
2013
|
1.52
|
|
13
|
Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease.
|
Mol Ther
|
2011
|
1.50
|
|
14
|
Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys.
|
Hum Gene Ther
|
2009
|
1.46
|
|
15
|
Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain.
|
Mol Ther
|
2008
|
1.40
|
|
16
|
Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy.
|
Cancer Res
|
2006
|
1.36
|
|
17
|
Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys.
|
Hum Gene Ther
|
2009
|
1.36
|
|
18
|
Striatal volume differences between non-human and human primates.
|
J Neurosci Methods
|
2008
|
1.33
|
|
19
|
Anterograde axonal transport of AAV2-GDNF in rat basal ganglia.
|
Mol Ther
|
2010
|
1.32
|
|
20
|
Effects of the perivascular space on convection-enhanced delivery of liposomes in primate putamen.
|
Exp Neurol
|
2005
|
1.32
|
|
21
|
Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.
|
Mol Ther
|
2010
|
1.31
|
|
22
|
Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.
|
Stereotact Funct Neurosurg
|
2011
|
1.30
|
|
23
|
Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
|
Neuro Oncol
|
2006
|
1.29
|
|
24
|
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
|
Neuro Oncol
|
2006
|
1.26
|
|
25
|
Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model.
|
Cancer Res
|
2004
|
1.26
|
|
26
|
Canine model of convection-enhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging: laboratory investigation.
|
J Neurosurg
|
2008
|
1.25
|
|
27
|
Optimized cannula design and placement for convection-enhanced delivery in rat striatum.
|
J Neurosci Methods
|
2009
|
1.25
|
|
28
|
Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates.
|
Neuroimage
|
2009
|
1.24
|
|
29
|
Real-time imaging and quantification of brain delivery of liposomes.
|
Pharm Res
|
2006
|
1.22
|
|
30
|
Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys.
|
Hum Gene Ther
|
2009
|
1.21
|
|
31
|
Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts.
|
Neuro Oncol
|
2007
|
1.21
|
|
32
|
Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery.
|
J Neurosci Methods
|
2006
|
1.17
|
|
33
|
Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.
|
J Neurosci
|
2010
|
1.14
|
|
34
|
Safety of real-time convection-enhanced delivery of liposomes to primate brain: a long-term retrospective.
|
Exp Neurol
|
2007
|
1.14
|
|
35
|
Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors.
|
Mol Ther
|
2010
|
1.09
|
|
36
|
Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.
|
Hum Gene Ther
|
2014
|
1.08
|
|
37
|
Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.
|
Neurosurg Focus
|
2006
|
1.06
|
|
38
|
An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
|
Brain Res
|
2011
|
1.05
|
|
39
|
Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase I study for the treatment of Parkinson disease.
|
Neurosurgery
|
2010
|
1.05
|
|
40
|
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
|
Cancer Res
|
2006
|
1.04
|
|
41
|
AAV9: over the fence and into the woods . . .
|
Mol Ther
|
2011
|
1.04
|
|
42
|
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen.
|
Neuroimage
|
2010
|
1.02
|
|
43
|
Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum.
|
Hum Gene Ther
|
2012
|
1.02
|
|
44
|
Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics.
|
J Neurosurg
|
2010
|
0.99
|
|
45
|
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
|
Neuro Oncol
|
2010
|
0.97
|
|
46
|
Convection-enhanced delivery of liposomes to primate brain.
|
Methods Enzymol
|
2009
|
0.96
|
|
47
|
T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery.
|
Neurosurgery
|
2011
|
0.93
|
|
48
|
Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain.
|
Neurobiol Dis
|
2011
|
0.93
|
|
49
|
Controlled dissemination of AAV vectors in the primate brain.
|
Prog Brain Res
|
2009
|
0.93
|
|
50
|
Design of an in-dwelling cannula for convection-enhanced delivery.
|
J Neurosci Methods
|
2010
|
0.93
|
|
51
|
Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
|
J Neurooncol
|
2009
|
0.90
|
|
52
|
Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models.
|
Neurosurgery
|
2008
|
0.90
|
|
53
|
Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies.
|
Mol Ther
|
2015
|
0.90
|
|
54
|
Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain.
|
Hum Gene Ther
|
2012
|
0.89
|
|
55
|
Gene therapy for Parkinson's disease: from non-human primates to humans.
|
Curr Opin Mol Ther
|
2010
|
0.88
|
|
56
|
PET 6-[F]fluoro-L-m-tyrosine Studies of Dopaminergic Function in Human and Nonhuman Primates.
|
Front Hum Neurosci
|
2008
|
0.88
|
|
57
|
Ultrasound-enhanced drug transport and distribution in the brain.
|
AAPS PharmSciTech
|
2010
|
0.86
|
|
58
|
Advances in thin tissue Golgi-Cox impregnation: fast, reliable methods for multi-assay analyses in rodent and non-human primate brain.
|
J Neurosci Methods
|
2013
|
0.85
|
|
59
|
Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A.
|
Mol Ther
|
2012
|
0.84
|
|
60
|
Gene therapy for Parkinson's disease: where are we now and where are we going?
|
Expert Rev Neurother
|
2010
|
0.84
|
|
61
|
The use of convection-enhanced delivery with liposomal toxins in neurooncology.
|
Toxins (Basel)
|
2011
|
0.83
|
|
62
|
Analysis of a simulation algorithm for direct brain drug delivery.
|
Neuroimage
|
2011
|
0.83
|
|
63
|
Anatomic compression caused by high-volume convection-enhanced delivery to the brain.
|
Neurosurgery
|
2009
|
0.82
|
|
64
|
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain.
|
Neuropharmacology
|
2010
|
0.81
|
|
65
|
Evaluation of an AAV2-based rapamycin-regulated glial cell line-derived neurotrophic factor (GDNF) expression vector system.
|
PLoS One
|
2011
|
0.80
|
|
66
|
Gene therapy for misfolding protein diseases of the central nervous system.
|
Neurotherapeutics
|
2013
|
0.77
|
|
67
|
Automated segmentation tool for brain infusions.
|
PLoS One
|
2013
|
0.77
|
|
68
|
Evaluation of pressure-driven brain infusions in nonhuman primates by intra-operative 7 Tesla MRI.
|
J Magn Reson Imaging
|
2012
|
0.77
|
|
69
|
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications.
|
Pharmaceuticals (Basel)
|
2012
|
0.77
|
|
70
|
Human/nonhuman primate AC-PC ratio--considerations for translational brain measurements.
|
J Neurosci Methods
|
2010
|
0.76
|
|
71
|
Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors.
|
Nanomedicine (Lond)
|
2014
|
0.76
|
|
72
|
Rapid inverse planning for pressure-driven drug infusions in the brain.
|
PLoS One
|
2013
|
0.76
|
|
73
|
Systemic rapamycin alone may not be a treatment option for malignant glioma: evidence from an in vivo study.
|
J Neurooncol
|
2012
|
0.75
|